Neisseria meningitidis Infections – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Neisseria meningitidis Infections – Pipeline Review, H1 2018’, provides an overview of the Neisseria meningitidis Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections

– The report reviews pipeline therapeutics for Neisseria meningitidis Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neisseria meningitidis Infections therapeutics and enlists all their major and minor projects

– The report assesses Neisseria meningitidis Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neisseria meningitidis Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neisseria meningitidis Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

China National Pharmaceutical Group Corp

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

ImmunoBiology Ltd

Johnson & Johnson

MGB Biopharma Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neisseria meningitidis Infections Overview

Neisseria meningitidis Infections Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neisseria meningitidis Infections Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neisseria meningitidis Infections Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

China National Pharmaceutical Group Corp

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

ImmunoBiology Ltd

Johnson & Johnson

MGB Biopharma Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Neisseria meningitidis Infections Drug Profiles

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae [serotype B] + meningococcal) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MenBioVax Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal (tetravalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W, Y] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W135] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes C, Y] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine 2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGBBP-3 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCL-195 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis [serotype B] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06886992 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-10 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis Infections Dormant Projects

Neisseria meningitidis Infections Discontinued Products

Neisseria meningitidis Infections Product Development Milestones

Featured News & Press Releases

Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease

Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection

Mar 24, 2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine)

Dec 24, 2014: Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial

Aug 01, 2013: US FDA expands Novartis' Menveo indication for infants aged two months

Feb 25, 2013: CanSinotech submitted CTA of “ACW135Y Meningococcal Conjugate Vaccine” to CFDA

Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Menveo

Feb 13, 2012: FDA Requests Additional Data On Novartis's Quadrivalent Meningococcal Conjugate Vaccine, Menveo For Expanded Use In Infants And Toddlers

Jun 16, 2011: FDA Accepts Novartis's Menveo sBLA For Review

May 12, 2011: Novartis Provides Update On Phase III Study Of Menveo Vaccine To Treat Meningococcal Disease

Jan 31, 2011: FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo, for use in children from 2 years of age

Oct 25, 2010: Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants

Jun 08, 2010: Novartis receives Health Canada approval of Menveo to prevent meningococcal disease

Mar 31, 2010: New vaccine can protect travelers against four types of meningitis

Mar 18, 2010: Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Neisseria meningitidis Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Neisseria meningitidis Infections Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Neisseria meningitidis Infections Pipeline by Biological E Ltd, H1 2018

Neisseria meningitidis Infections Pipeline by China National Pharmaceutical Group Corp, H1 2018

Neisseria meningitidis Infections Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018

Neisseria meningitidis Infections Pipeline by GlaxoSmithKline Plc, H1 2018

Neisseria meningitidis Infections Pipeline by ImmunoBiology Ltd, H1 2018

Neisseria meningitidis Infections Pipeline by Johnson & Johnson, H1 2018

Neisseria meningitidis Infections Pipeline by MGB Biopharma Ltd, H1 2018

Neisseria meningitidis Infections Pipeline by Pfizer Inc, H1 2018

Neisseria meningitidis Infections Pipeline by Sanofi Pasteur SA, H1 2018

Neisseria meningitidis Infections Pipeline by Serum Institute of India Ltd, H1 2018

Neisseria meningitidis Infections Pipeline by Wellstat Vaccines LLC, H1 2018

Neisseria meningitidis Infections Dormant Projects, H1 2018

Neisseria meningitidis Infections Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Neisseria meningitidis Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports